Question 1

What is China — National Medical Products Administration?

Accepted Answer

China — National Medical Products Administration is a Entity.

Question 2

How often does China — National Medical Products Administration appear in global news?

Accepted Answer

Tracked across 10 news events drawn from 75 articles.

Question 3

When was China — National Medical Products Administration first tracked by NewsDesk?

Accepted Answer

First tracked on Apr 08, 2026.

Question 4

When was China — National Medical Products Administration last mentioned in news?

Accepted Answer

Last active on Jun 12, 2026.

Question 5

What is China — National Medical Products Administration's current news sentiment?

Accepted Answer

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is China — National Medical Products Administration in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 10 events.

Question 7

What is the most recent event involving China — National Medical Products Administration?

Accepted Answer

Harbour BioMed HBM7004 IND Accepted by NMPA (Jun 10, 2026, 7 articles).

Question 8

Who is China — National Medical Products Administration most connected to?

Accepted Answer

Top relationships: American Society of Clinical Oncology, American Society of Clinical Oncology, China.

Question 9

How did the "Harbour BioMed HBM7004 IND Accepted by NMPA" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration (NMPA) of China accepted the Investigational New Drug (IND) application for HBM7004, allowing Harbour BioMed to advance its drug towards clinical evaluation in China.

Question 10

How did the "Antengene ATG-201 IND Approval China" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration approved the IND application for ATG-201, enabling Antengene to proceed with Phase I clinical trials in China.

Question 11

How did the "Akeso's gumokimab approved in China" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration approved Gumokimab, enabling its commercialization in China and providing a new treatment option for patients with moderate-to-severe plaque psoriasis.

Question 12

How did the "IBI363 Shows Survival Benefits in NSCLC" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration (NMPA) of China has granted three Breakthrough Therapy Designations to IBI363, recognizing its potential for significant clinical advantage over existing therapies.

Question 13

How did the "Dizal Presents Positive NSCLC Data" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration (NMPA) of China approved golidocitinib in June 2024 for r/r PTCL, indicating regulatory progress for one of Dizal Pharmaceutical's key assets.

Question 14

How did the "Kelun-Biotech sac-TMT Phase III Results" event impact China — National Medical Products Administration?

Accepted Answer

The agency has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for review, indicating regulatory recognition of the drug's potential.

Question 15

How did the "Arrowhead Presents Positive Plozasiran Data" event impact China — National Medical Products Administration?

Accepted Answer

China's China — National Medical Products Administration previously approved REDEMPLO (plozasiran), further solidifying its international market approvals.

Question 16

How is this data collected?

Accepted Answer

NewsDesk aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.